Sugi Predict

Sugi Predict / Compounds / SCHEMBL14701593

SCHEMBL14701593

SCHEMBL14701593

CC(C)c1coc(-c2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.46
▸ ENPP3 O14638 2/20 0.45
▸ ENPP1 P22413 2/20 0.45
▸ HDAC1 Q13547 2/20 0.44
▸ HDAC8 Q9BY41 2/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.44
▸ NPC1 O15118 4/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HPGD P15428 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ DRD2 P14416 2/20 0.40
▸ DRD4 P21917 2/20 0.40
▸ DRD3 P35462 2/20 0.40
▸ PDE4B Q07343 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23558942 0.85 ALDH1A1 (0.44) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL7210652 0.85 ALDH1A1 (0.47) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL7158026 0.85 ALDH1A1 (0.47) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL30765878 0.85 ALDH1A1 (0.47) ALDH1A1ENPP3ENPP1HDAC1HDAC8
Hydrochloric Acid SCHEMBL30765949 0.84 ALDH1A1 (0.46) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL21721696 0.81 NPC1 (0.47) ALDH1A1HDAC1HDAC8HDAC6NPC1
SCHEMBL4033224 0.80 ENPP3 (0.49) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL28369533 0.80 ENPP3 (0.33) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL28373960 0.80 ENPP3 (0.33) ALDH1A1ENPP3ENPP1HDAC1HDAC8
SCHEMBL1200641 0.77 HSD17B10 (0.35) RAB9AKDM4EHSD17B10NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040461-A Spirobarbitudes compound, preparation method and application 北京工业大学 2025-05-27 — — CN disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
US-11873290-B2 — — 2024-01-16 — — US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 — — EP disclosed
EP-3877376-B1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2023-08-23 — — EP disclosed
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS ALS THERAPY DEVELOPMENT INSTITUTE, 2023-02-23 — — US disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 — — WO disclosed
US-11091464-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2021-08-17 — — US disclosed
US-9751858-B2 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2017-09-05 — — US disclosed
US-9670157-B2 Benzylamine derivatives KALVISTA PHARMACEUTICALS LIMITED (GB) 2017-06-06 — — US disclosed
US-20170008857-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-01-12 — — US disclosed
US-20160237060-A1 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2016-08-18 — — US disclosed
US-9353068-B2 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2016-05-31 — — US disclosed
US-9284350-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2016-03-15 — — US disclosed
US-20160039752-A1 BENZYLAMINE DERIVATIVES KALVISTA PHARMACEUTICALS LIMITED (GB) 2016-02-11 — — US disclosed
US-20130053416-A1 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2013-02-28 — — US disclosed
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC. (CA) 2013-02-14 — — US disclosed
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS PHARMASCIENCE INC. (CA) 2013-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873290-B2 — IL6, MUSK, IL6ST ALDH1A1 190/4885ENPP3 947/4885ENPP1 370/4885
US-20130040892-A1 IAP BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC2, BIRC3 ALDH1A1 4122/4885ENPP3 3907/4885ENPP1 2739/4885
US-20230054997-A1 COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SOD1, SMN1; SMN2, CLN6 ALDH1A1 1721/4885ENPP3 3253/4885ENPP1 3180/4885
US-20170008857-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN ALDH1A1 4550/4885ENPP3 892/4885ENPP1 1046/4885
US-20160237060-A1 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS CTSF, CTSS, CTSV ALDH1A1 1184/4885ENPP3 865/4885ENPP1 1197/4885
US-20130053416-A1 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS CTSF, CTSS, CTSV ALDH1A1 1533/4885ENPP3 789/4885ENPP1 1179/4885
US-11091464-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A ALDH1A1 270/4885ENPP3 878/4885ENPP1 256/4885
US-20160039752-A1 BENZYLAMINE DERIVATIVES BDKRB1, BDKRB2, KLKB1 ALDH1A1 2364/4885ENPP3 2060/4885ENPP1 1941/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A ALDH1A1 270/4885ENPP3 878/4885ENPP1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.